Star Lake Bioscience Co (SHSE:600866) Cyclically Adjusted Revenue per Share: ¥5.94 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600866 Star Lake Bioscience Co Inc SHSE:600866
62 GF Score
Price ¥4.48
GF Value ¥5.44
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is Star Lake Bioscience Co Cyclically Adjusted Revenue per Share?

Star Lake Bioscience Co SHSE:600866 +1.13% 62 Cyclically Adjusted Revenue per Share is ¥5.94 as of Mar. 2026. GuruFocus rates SHSE:600866 with a GF Score™ of 62/100 and a GF Value™ of ¥5.44 (Modestly Undervalued). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Star Lake Bioscience Co's adjusted revenue per share for the three months ended in Mar. 2026 was ¥2.249. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ¥5.94 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Star Lake Bioscience Co's average Cyclically Adjusted Revenue Growth Rate was 17.40% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 21.80% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 30.20% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 11.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Star Lake Bioscience Co was 36.80% per year. The lowest was -6.20% per year. And the median was 6.70% per year.

As of today (2026-08-10), Star Lake Bioscience Co's current stock price is ¥4.48. Star Lake Bioscience Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was ¥5.94. Star Lake Bioscience Co's Cyclically Adjusted PS Ratio of today is 0.75.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Star Lake Bioscience Co was 4.48. The lowest was 0.74. And the median was 2.28.


Star Lake Bioscience Co  (SHSE:600866) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Star Lake Bioscience Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=4.48/5.94
=0.75

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Star Lake Bioscience Co was 4.48. The lowest was 0.74. And the median was 2.28.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Star Lake Bioscience Co Cyclically Adjusted Revenue per Share Related Terms


Star Lake Bioscience Co Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Star Lake Bioscience Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Star Lake Bioscience Co Cyclically Adjusted Revenue per Share Chart

Star Lake Bioscience Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.89 3.16 3.98 4.84 5.71

Star Lake Bioscience Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.06 5.26 5.49 5.71 5.94

SHSE:600866 vs VRTX, REGN, RVMD: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Star Lake Bioscience Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Star Lake Bioscience Co Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Star Lake Bioscience Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Star Lake Bioscience Co's Cyclically Adjusted PS Ratio falls into.


SHSE:600866
62GF Score
Star Lake Bioscience Co Inc SHSE:600866
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Star Lake Bioscience Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Star Lake Bioscience Co's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=2.249/116.3033*116.3033
=2.249

Current CPI (Mar. 2026) = 116.3033.

Star Lake Bioscience Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.263 101.400 0.302
201609 0.261 102.400 0.296
201612 0.378 102.600 0.428
201703 0.175 103.200 0.197
201706 0.257 103.100 0.290
201709 0.314 104.100 0.351
201712 0.345 104.500 0.384
201803 0.359 105.300 0.397
201806 0.330 104.900 0.366
201809 0.309 106.600 0.337
201812 0.452 106.500 0.494
201903 0.426 107.700 0.460
201906 0.329 107.700 0.355
201909 0.393 109.800 0.416
201912 0.265 111.200 0.277
202003 0.388 112.300 0.402
202006 0.404 110.400 0.426
202009 0.299 111.700 0.311
202012 0.420 111.500 0.438
202103 0.411 112.662 0.424
202106 0.398 111.769 0.414
202109 0.354 112.215 0.367
202112 3.179 113.108 3.269
202203 3.643 114.335 3.706
202206 4.064 114.558 4.126
202209 3.539 115.339 3.569
202212 3.504 115.116 3.540
202303 2.504 115.116 2.530
202306 2.470 114.558 2.508
202309 2.688 115.339 2.710
202312 2.793 114.781 2.830
202403 2.528 115.227 2.552
202406 2.580 114.781 2.614
202409 2.589 115.785 2.601
202412 2.736 114.893 2.770
202503 2.431 115.116 2.456
202506 2.479 114.907 2.509
202509 2.359 115.471 2.376
202512 2.301 115.832 2.310
202603 2.249 116.303 2.249

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ¥5.94 mean?
Star Lake Bioscience Co (SHSE:600866) has a Cyclically Adjusted Revenue per Share of ¥5.94 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Star Lake Bioscience Co and its competitors.
Is Star Lake Bioscience Co's Cyclically Adjusted Revenue per Share too high?
Star Lake Bioscience Co's current Cyclically Adjusted Revenue per Share is ¥5.94. Overall, Star Lake Bioscience Co has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Star Lake Bioscience Co's Cyclically Adjusted Revenue per Share compare to VRTX and REGN?
Star Lake Bioscience Co's Cyclically Adjusted Revenue per Share of ¥5.94 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Star Lake Bioscience Co and its competitors. Star Lake Bioscience Co's current Cyclically Adjusted Revenue per Share is ¥5.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Star Lake Bioscience Co stock overvalued right now?
Based on GuruFocus' analysis, Star Lake Bioscience Co (SHSE:600866) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥5.44, compared to a current price of ¥4.48 — trading 17.6% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is ¥5.94. Star Lake Bioscience Co's overall GF Score™ is 62/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Star Lake Bioscience Co (SHSE:600866), the current Cyclically Adjusted Revenue per Share is ¥5.94 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Star Lake Bioscience Co (SHSE:600866) Overvalued in 2026?

Based on GuruFocus' analysis, Star Lake Bioscience Co stock appears to be undervalued. The current stock price of ¥4.48 is trading 17.6% below its estimated GF Value™ of ¥5.44. GuruFocus considers Star Lake Bioscience Co to be Modestly Undervalued.

Key valuation signals for SHSE:600866:

  • Cyclically Adjusted Revenue per Share: ¥5.94
  • GF Value™: ¥5.44 vs. price of ¥4.48 (17.6% below fair value)
  • GF Score™: 62/100 with 7 warning signs

No single metric tells the full story. See the SHSE:600866 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Star Lake Bioscience Co Business Description

Address No. 67 Gongnong North Road, Guangdong Province, Zhaoqing, CHN, 526060
Star Lake Bioscience Co Inc is a China-based Pharmaceutical manufacturer. The company is mainly engaged in the research, development, production, and sales of chemical raw materials and pharmaceutical intermediates. Products offered by the company include proline, guanosine, adenosine, adenine, adefovir dipivoxil, memantine hydrochloride, Proline, threonine, lysine, among others. Its products are used in food processing, feed processing, and pharmaceutical manufacturing. Star Lake sells its products through direct sales and distributors in China and overseas markets.
62GF Score

Get the complete analysis for SHSE:600866

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥4.48
Price
¥5.44
GF Value